SCHEMBL358841

SCHEMBL358841

CC(C)C(=O)OCCOC(=O)Nc1cc[c]cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
HPGD P15428 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RECQL P46063 1/20 0.44
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
BCHE P06276 1/20 0.42
CASP1 P29466 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2535856 0.82 SMN1; SMN2 (0.62) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL966501 0.80 NPSR1 (0.46) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL122021 0.79 RAB9A (0.64) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL1490972 0.78 RAB9A (0.57) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL358839 0.78 HPGD (0.43) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL23017397 0.78 RAB9A (0.63) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL964220 0.78 NPC1 (0.45) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL363979 0.76 HPGD (0.41) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL28184225 0.76 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1
SCHEMBL7918203 0.75 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012009646-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 WO disclosed